Evidence map›Paper›PMID 39958601›Full record

ArticleMissouri medicine

From Serendipity to Scalability in Rare Disease Patient Collaborations.

Kerry Grens, Judith L Weisenberg, Robin C Ryther, Harrison W Gabel

Abstract read
In one paragraph

Article in Missouri medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kerry GrensVice President of the Tatton Brown Rahman Syndrome Community, Stanfordville, New York.
Judith L WeisenbergWashington University School of Medicine Division of Pediatric Neurology, Department of Neurology, St. Louis, Missouri.
Robin C RytherWashington University School of Medicine Division of Pediatric Neurology, Department of Neurology, St. Louis, Missouri.
Harrison W GabelAssociate Professor, Washington University School of Medicine, Department of Neuroscience, St. Louis, Missouri.

Funding

MECHANISMS OF EPIGENETIC REGULATION IN NERVOUS SYSTEM DEVELOPMENTR01MH117405 · NIMH · WASHINGTON UNIVERSITY · PI Harrison W Gabel · 2019 to 2026
$3.9M
Exploring Feasibility of Gene-Targeted Therapeutics for Epigenetic Neurodevelopmental DisordersR21NS137088 · NINDS · WASHINGTON UNIVERSITY · PI GABEL, HARRISON W · 2024 to 2025
$428k
NIMH NIH HHS R01 MH117405NINDS NIH HHS R21 NS137088
6 · The paper itself

Abstract

As the rate of diagnosis for rare disease increases, so does the need to develop scalable solutions to address patient community needs. Drawing upon our experiences in rare intellectual and developmental disability research, advocacy, and treatment, we present two examples of how collaboration between patient groups, clinicians, and investigators at Washington University in St. Louis have generated invaluable resources to accelerate toward treatments. These successful partnerships serve as models for building research and clinical infrastructure for rare diseases.

Indexed as

Cooperative BehaviorRare DiseasesHumansMissouri

Identifiers

PMID39958601
PMCPMC11827657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.